-
Mashup Score: 4Bronchial Thermoplasty in the Biologic Era - 5 month(s) ago
Asthma is a chronic disease of airway inflammation and airway hyperresponsiveness due to smooth muscle hyperreactivity, complicated by exacerbations leading to significant morbidity and mortality. Despite major advances in pharmacotherapy, therapeutic options for the smooth muscle are lacking and many patients remain uncontrolled.1 Bronchial thermoplasty (BT) is a nonpharmacologic treatment of severe asthma in which thermal energy is applied to the airway walls to decrease smooth muscle mass and the effects of airway hyperreactivity.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0
To the Editor: The long-term treatment of psoriasis with biologics is associated with a gradual decrease of efficacy, leading to treatment discontinuation in a significant proportion of patients.1-3 As such, prognostic tools might be useful in optimizing long-term outcomes of biologic treatment. In this study, we compared the accuracy of a traditional statistical risk factor-based model versus machine learning (ML) in predicting the 5-year probability of biologic drug discontinuation.
Source: www.jaad.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 3Controversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children? - 7 month(s) ago
The availability of biologic agents for patients with severe asthma has increased dramatically over the last several decades. The absence of direct head-to-head comparative data and relative lack of biomarkers to predict response can make it difficult to choose the right biologic medication for a given patient. Selecting a biologic agent for the pediatric population presents further challenges due to more limited approved biologic agents and fewer clinical trials in children. In addition, the outcome data that are currently available suggest that treatment responses for a given biologic may be different between adult and pediatric patients.
Source: www.jaci-inpractice.orgCategories: Allergy-Immunology, Latest HeadlinesTweet
-
Mashup Score: 0Expedited Programs and New Approvals in Oncology (2013 – Present) - Friends of Cancer Research - 9 month(s) ago
Using publicly available data from review documents on Drugs@FDA, Friends created this dashboard to show how four expedited programs impact the time it takes for a drug or biologic to be approved. This dashboard displays data on original therapeutic agents approved for use in oncology since January 2013 when the most recent expedited pathway, Breakthrough…
Source: Friends of Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Weighing the Options: Balancing Risk and Benefits as Biologic Therapies Expand Indications to Children - 10 month(s) ago
An American Academy of Dermatology Reading Room selection
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0CAR-T cell therapy, recent approvals put precision medicine ‘on the horizon’ for lupus - 10 month(s) ago
The recent success of chimeric antigen receptor-T cell therapy, along with three high-profile FDA approvals, may help make precision medicine a reality in lupus, according to a presenter at the Biologic Therapies Summit.“It is prime time for biologic therapies and the treatment of lupus,” Emily Littlejohn, DO, MPH, of the department of rheumatologic and immunologic disease at the
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Depression, treatment order impact biologic therapy persistence in psoriatic arthritis - 12 month(s) ago
Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.“The development of new biological disease-modifying antirheumatic drugs (bDMARDs) for PsA has led to better disease control as well as slowing of
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Depression, treatment order impact biologic therapy persistence in psoriatic arthritis - 12 month(s) ago
Biologic therapy persistence in psoriatic arthritis often depends on whether the drug was a first or second treatment, with depression, anxiety, older age and higher tender joint count also leading to discontinuation, according to data.“The development of new biological disease-modifying antirheumatic drugs (bDMARDs) for PsA has led to better disease control as well as slowing of
Source: www.healio.comCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 11FDA Approves Sarilumab for Polymyalgia Rheumatica - 12 month(s) ago
Sarilumab offers a new treatment option for PMR, reducing reliance on corticosteroids. Learn about the benefits and risks.
Source: CreakyJointsCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 0Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations - 12 month(s) ago
FDA approval of dupilumab for moderate-to-severe AD shifted the paradigm from use of broad, systemic immunosuppressants to a safer, targeted treatment and led to the emergence of newer interleukin (IL)-4/IL-13 directed biologics and small molecule therapies, namely Janus kinase (JAK) inhibitors. Tralokinumab and emerging (not yet approved) lebrikizumab, which both target IL-13, are alternative…
Categories: Allergy-Immunology, Latest HeadlinesTweet
In Current Issue (FREE)! #Bronchial #Thermoplasty in the #Biologic Era https://t.co/HiFZlRLmRq